Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Shoukat A, Bawden C, Röst G, LeBlanc J, Galvani A, Langley J, Moghadas S. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine 2024, 42: 1768-1776. PMID: 38368226, DOI: 10.1016/j.vaccine.2024.02.041.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsLong-term care homesCommunity-dwelling older adultsCanadian Immunization Research NetworkIncremental cost-effectiveness ratio valuesResidents of long-term care homesRSV diseaseOlder adultsBurden of RSV diseaseRespiratory syncytial virus diseaseNo-vaccination scenarioRSV-related hospitalisationNo vaccinesRespiratory syncytial virusVaccination programBudget impactSocietal perspectiveCost-effectiveness ratioReduction of hospitalizationInfluenza vaccineRSV seasonSyncytial virusHealth benefitsAnalysis of vaccination